These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8340920)

  • 1. Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.
    Huang HC; Reitz DB; Chamberlain TS; Olins GM; Corpus VM; McMahon EG; Palomo MA; Koepke JP; Smits GJ; McGraw DE
    J Med Chem; 1993 Jul; 36(15):2172-81. PubMed ID: 8340920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
    Kubo K; Kohara Y; Imamiya E; Sugiura Y; Inada Y; Furukawa Y; Nishikawa K; Naka T
    J Med Chem; 1993 Jul; 36(15):2182-95. PubMed ID: 8340921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.
    Kubo K; Inada Y; Kohara Y; Sugiura Y; Ojima M; Itoh K; Furukawa Y; Nishikawa K; Naka T
    J Med Chem; 1993 Jun; 36(12):1772-84. PubMed ID: 8510105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazolinones as nonpeptide angiotensin II antagonists. 1. Synthesis and evaluation of potent 2,4,5-trisubstituted triazolinones.
    Chang LL; Ashton WT; Flanagan KL; Strelitz RA; MacCoss M; Greenlee WJ; Chang RS; Lotti VJ; Faust KA; Chen TB
    J Med Chem; 1993 Aug; 36(17):2558-68. PubMed ID: 8355255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316.
    Olins GM; Corpus VM; McMahon EG; Palomo MA; Schuh JR; Blehm DJ; Huang HC; Reitz DB; Manning RE; Blaine EH
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1037-43. PubMed ID: 1602371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
    Ashton WT; Cantone CL; Chang LL; Hutchins SM; Strelitz RA; MacCoss M; Chang RS; Lotti VJ; Faust KA; Chen TB
    J Med Chem; 1993 Mar; 36(5):591-609. PubMed ID: 8496939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.
    Bovy PR; Reitz DB; Collins JT; Chamberlain TS; Olins GM; Corpus VM; McMahon EG; Palomo MA; Koepke JP; Smits GJ
    J Med Chem; 1993 Jan; 36(1):101-10. PubMed ID: 8421274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triazolinone biphenylsulfonamide derivatives as orally active angiotensin II antagonists with potent AT1 receptor affinity and enhanced AT2 affinity.
    Ashton WT; Chang LL; Flanagan KL; Hutchins SM; Naylor EM; Chakravarty PK; Patchett AA; Greenlee WJ; Chen TB; Faust KA
    J Med Chem; 1994 Aug; 37(17):2808-24. PubMed ID: 8064808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist.
    Olins GM; Corpus VM; Chen ST; McMahon EG; Palomo MA; McGraw DE; Smits GJ; Null CL; Brown MA; Bittner SE
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):617-25. PubMed ID: 7505365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996).
    Sircar I; Hodges JC; Quin J; Bunker AM; Winters RT; Edmunds JJ; Kostlan CR; Connolly C; Kesten SJ; Hamby JM
    J Med Chem; 1993 Aug; 36(16):2253-65. PubMed ID: 8360871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on nonpeptide angiotensin II receptor antagonists. II. Synthesis and biological evaluation of 5H-pyrazolo[1,5-b][1,2,4]triazole derivatives with a C-linked oxygen functional group at the 6-position.
    Okazaki T; Suga A; Watanabe T; Kikuchi K; Kurihara H; Shibasaki M; Fujimori A; Inagaki O; Yanagisawa I
    Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):287-93. PubMed ID: 9501463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes.
    Chang LL; Ashton WT; Flanagan KL; Chen TB; O'Malley SS; Zingaro GJ; Kivlighn SD; Siegl PK; Lotti VJ; Chang RS
    J Med Chem; 1995 Sep; 38(19):3741-58. PubMed ID: 7562905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
    Bernhart CA; Perreaut PM; Ferrari BP; Muneaux YA; Assens JL; Clément J; Haudricourt F; Muneaux CF; Taillades JE; Vignal MA
    J Med Chem; 1993 Oct; 36(22):3371-80. PubMed ID: 8230127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
    Wienen W; Mauz AB; Van Meel JC; Entzeroth M
    Mol Pharmacol; 1992 Jun; 41(6):1081-8. PubMed ID: 1614410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
    Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
    Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation.
    Virone-Oddos A; Desangle V; Provost D; Cazes M; Caussade F; Cloarec A
    Br J Pharmacol; 1997 Feb; 120(3):488-94. PubMed ID: 9031754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacology of SC-51316, a nonpeptidic angiotensin II receptor antagonist.
    Olins GM; Smits GJ; Koepke JP; Huang HC; Reitz DB; Manning RE; Blaine EH
    Am J Hypertens; 1993 Jul; 6(7 Pt 1):619-25. PubMed ID: 8398003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.